ArticleEndocrine2025
Verifying the oncologic rationale of prophylactic central compartment neck dissection in the management of papillary thyroid carcinoma using a pathologic spectrum of nodal metastases characteristics. A Prospective Comparative study.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDisease-free survival is the main outcome of interest considered when assessing the effectiveness of surgical management of papillary thyroid carcinoma (PTC). Specific characteristics of nodal metastases have been demonstrated to impact the risk of recurrence.
objectiveVerify the oncologic rationale of prophylactic central compartment neck dissection (pCCND) in the management of PTC by comparing the pathologic spectrum of lymph nodes in patient's undergoing pCCND vs. therapeutic CCND (tCCND).
methodsBetween May 2017 and October 2018, 257 patients underwent total thyroidectomy for PTC. pCCND was performed for clinically uninvolved nodes, and tCCND for clinically apparent nodal disease. Harvested metastatic nodes from each group were compared in terms of number, size, and the presence of extranodal extension. Cut-off values for the size and number were 2 mm and 5, respectively. Patients were followed until October 2023.
results78 patients underwent tCCND. Whereas pCCND was performed in 179 patients. The mean number of nodes harvested in tCCND was 14 (9-31), and 9 (5-24) in pCCND (p < 0.0001). Node positivity was 84.6, and 37.4%, respectively (p < 0.0001). ≥5 metastatic nodes were harvested in 66.6% of tCCND vs. 7.5% of pCCND (p < 0.0001). 73% of tCCND had a metastatic node ≥2 mm in size vs. 2.5% of pCCND (p < 0.0001). Extranodal extension occurred in 25% of tCCND vs. 2.5% of pCCND (p = 0.01). Recurrence rate was 3.8% in tCCND vs. none in pCCND (p = 0.008).
conclusionClinically inapparent nodal disease has a pathological spectrum with insignificant impact on disease recurrence. Therefore, pCCND does not seem to be oncologically meaningful.
Indexed as
Identifiers
40024949What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.